Frontiers in Pharmacology | Gastrointestinal and Hepatic Pharmacology

Original Research

Published on 04 Apr 2025

MiR-3613-5p targets AQP4 to promote the progression of chronic atrophic gastritis to gastric cancer

in Gastrointestinal and Hepatic Pharmacology

Jian Bi
Yufen Wang
Yingde Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1523689

Original Research

Published on 04 Apr 2025

Suppressed intestinal secondary bile acids in moxifloxacin-induced hyperglycemia: studies in normal and diabetic GK rats

in Gastrointestinal and Hepatic Pharmacology

Yewen Sun
Yuchen Qu
Zhuan Yang
Bo Lv
Guanjun Wang
Kai Fan
Yuyuan Wang
Jie Pan
Ziyan Du
Yunli Yu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1569856

Original Research

Published on 04 Apr 2025

Alpha-estradiol and (R)-(−)-ibuprofen inhibit gastric cancer progression via GLI1 G-quadruplex

in Gastrointestinal and Hepatic Pharmacology

Qiang Li
Pan Pan
Qingqing Xian
Jingtan Li
Jingting Wang
Jiaying Cai
Jing Wang
Yanfei Jia
Haiji Sun
Lulu Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1492694

Review

Accepted on 03 Apr 2025

Understanding the Complex Role of Exosomes in Intestinal Ischemia-Reperfusion Injury: From Pathogenesis to Protection

in Gastrointestinal and Hepatic Pharmacology

Qin Ye
Zi-Hang Yu
Liang Nie
Feixiang Wang
Guo Mu
Bin Lu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1533628

Original Research

Published on 03 Apr 2025

Paricalcitol alleviates intestinal ischemia-reperfusion injury via inhibition of the ATF4-CHOP pathway

in Gastrointestinal and Hepatic Pharmacology

Jiawei Zhang
Tingting Liu
Tongqing Xue
Zhongzhi Jia

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1529343

Brief Research Report

Published on 02 Apr 2025

Andrographis paniculata restores gut health by suppressing inflammation and strengthening mucosal immunity

in Gastrointestinal and Hepatic Pharmacology

Vidushi Tyagi
Ashish Kumar
Karuna Shanker
Anirban Pal

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1536683

143 views

Systematic Review

Published on 01 Apr 2025

Inflammatory bowel disease therapeutics: a bibliometric analysis of tofacitinib research in ulcerative colitis

in Gastrointestinal and Hepatic Pharmacology

Jianping Zhou
Yuting Xi
Yaping Zhang
Rui Zhang
Hao Fu
Ce Zhou

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1570238

204 views

Original Research

Accepted on 31 Mar 2025

Effect of propinox and pinaverium bromide on ex vivo colonic motor patterns and their synergistic effect with hyoscine butyl bromide

in Gastrointestinal and Hepatic Pharmacology

Sara Traserra
Luis Gerardo Alcalá-González
Claudia Barber
Stefania Landolfi
Carolina Malagelada
Robert Lange
Terence Appelqvist
Maura Corsetti
Marcel Jimenez

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1491123

Original Research

Accepted on 31 Mar 2025

Macrophage PKM2 depletion ameliorates hepatic inflammation and acute liver injury in mice

in Gastrointestinal and Hepatic Pharmacology

Ziwei Kang
Zhiwei Chen
Jincheng Li
Ruoyan Xie
Jinyu Lv
Weijia Ye
Yiming Cui
Peixin Zhao
Keke Zhang
Jian Hong

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1546045

Review

Accepted on 28 Mar 2025

The Role of Hepatic Sinusoidal Microenvironment in NASH: Pathogenesis, Animal Models, and Therapeutic Prospects

in Gastrointestinal and Hepatic Pharmacology

Wanying Tan
Jiangting Deng
Lingjun Qi
Zhenghuai Tan

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1467950

Systematic Review

Published on 28 Mar 2025

Research trends of nanomaterials in Helicobacter pylori: a bibliometric analysis from 2003 to 2023

in Gastrointestinal and Hepatic Pharmacology

Yeqing Lei
Tao Chen
Qin Du
Weihua Yu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1546395

157 views

Original Research

Accepted on 27 Mar 2025

Mirabegron induces selective changes in the faecal microbiota of HFHFr rats without altering bile acid composition

in Gastrointestinal and Hepatic Pharmacology

Roger Bentanachs
Lluïsa Miró
Patricia Ramírez-Carrasco
Rosa M Sánchez
Manuel Bernabeu Lorenzo
Concepció Amat
Marta Alegret Jorda
Anna Pérez-Bosque
Núria Roglans
Joan Carles Laguna

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1547749

Review

Published on 27 Mar 2025

Mechanism and therapeutic potential of liver injury induced by cholesterol-associated proteins

in Gastrointestinal and Hepatic Pharmacology

Yourong Zhou
Yashi Cao
Yiming Yin
Zhifei Xu
Xiaochun Yang
Bo Yang
Peihua Luo
Hao Yan
Qiaojun He

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1572592

231 views

Correction

Published on 27 Mar 2025

Corrigendum: Cynaroside ameliorates TNBS-induced colitis by inhibiting intestinal epithelial cell apoptosis via the PI3K/AKT signalling pathway

in Gastrointestinal and Hepatic Pharmacology

Ju Huang
Jing Li
Zhijun Geng
Lixia Yin
Minzhu Niu
Qingqing Li
Xinyue Liu
Xinke Cheng
Xiaofeng Zhang
Xue Song

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1591086

126 views

Original Research

Published on 27 Mar 2025

Gut microbiota and HMGB1/NLRP3/GSDMD inflammasome-dependent pyroptosis: mechanisms by physcion ameliorates alcoholic liver fibrosis

in Gastrointestinal and Hepatic Pharmacology

Ting Bai
Hao-Lin Guo
Fei Wang
Yan-Yu Kang
Hao-Tian Zhang
Lu Dong
Yong Yang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1532590

198 views

Review

Accepted on 26 Mar 2025

Endogenous Micropeptides as potential diagnostic biomarkers and therapeutic drugs

in Gastrointestinal and Hepatic Pharmacology

AIXI ZHONG
Shuai Li
Jingxuan Zhang
Jingyuan Zhao
Chenhui Yao

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1545575